Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Abstract 1956: miR-181d degradation mediated genetic heterogeneity and acquired resistance
Ramakrishnan, Valya, Akers, Johnny, Nguyen, Thien , Wang, Aaron , Adhikari, Bandita, Hirshman, Brian R. , Hua, Wei , Ying, Mao, Nitta, Masayuki, Chen, Clark C. , Li, Jie , Sarkaria, Jann N. , Hua, Wei, Ying, Mao, Jiang, Tao , Carter, Bob S.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 1956-1956

10.1158/1538-7445.am2018-1956 Get It

Abstract When unrepaired, alkylated DNA can induce cell death or trigger mutagenesis. Cellular capacity for repair of these lesions by O6-methylguanine methyltransferase (MGMT) dictates the equilibrium between cell viability and genetic diversity. Treatment of glioblastoma cells with temozolomide (TMZ) induced ATM- and Rad3-related (ATR) kinase dependent polyribonucleotide nucleotidyltransferase 1 (PNPT1) degradation of miR-181d. miR-181d suppresses MGMT expression; its degradation increases the mean MGMT expression of the cell population. miR-181d degradation also magnifies the cell-to-cell variability in MGMT expression, expanding the genetic heterogeneity of the population. This expanded heterogeneity enhances the “fitness” of the population and constitutes a novel form of chemotherapeutic resistance. These effects can be suppressed by overexpression of miR-181d, suggesting miRNA delivery as a strategy for glioblastoma therapy. To characterize the mechanism of acquired resistance, we profiled the expression of 2400 miRNAs before and after TMZ treatment. In independent patient-derived neurosphere lines, the majority of miRNAs remained unchanged after treatment. However, miR-181d was consistently suppressed after TMZ treatment. Our previous work demonstrated miR-181d as the master regulator of MGMT. We confirmed TMZ-induced suppression of miR-181d using independent in vitro and in vivo models as well as matched pre- and post-TMZ treated clinical specimens. TMZ-induced miR-181d suppression persisted after transcriptional inhibition, suggesting degradation as the primary mechanism. We performed an siRNA screen and identified polyribonucleotide nucleotidyltransferase 1 (PNPT1) as the gene responsible for miR-181d degradation. CRISPR inactivation of PNPT1 eliminated TMZ-induced suppression of miR-181d; this was rescued by wild-type PNPT1 but not by PNPT1 harboring RNAse-inactivating mutations. TMZ-induced degradation of miR-181d requires ATR kinase. Silencing or inhibition of ATR eliminated binding of PNPT1 to miR-181d and prevented degradation of miR-181d. TMZ-sensitizing effects of ATR inhibition were reversed by anti-miR-181d, suggesting miR-181d is essential in this process. In addition to elevating the mean MGMT expression of the population, single-cell analysis revealed that miR-181d degradation broadened the cell-to-cell variability in MGMT expression in vitro. In matched clinical pre- and post-TMZ treated specimens, variability in MGMT expression was significantly elevated in post-TMZ samples. This was recapitulated using The Cancer Genome Atlas (TCGA) database. We propose that miR-181d degradation-mediated expansion of genetic heterogeneity enhances the “fitness” of the population, constituting a novel form of chemotherapeutic resistance. These effects are suppressed by miR-181d overexpression, suggesting miRNA delivery as a strategy for glioblastoma therapy. Citation Format: Valya Ramakrishnan, Johnny Akers, Thien Nguyen, Aaron Wang, Bandita Adhikari, Brian Hirshman, Jie Li, Jann Sarkaria, Wei Hua, Mao Ying, Masayuki Nitta, Tao Jiang, Bob Carter, Clark C. Chen. miR-181d degradation mediated genetic heterogeneity and acquired resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1956.
Abstract 242: Large pathway and gene set analysis of GWAS data identifies novel associations for pancreatic cancer
Zhang, Han , Hyland, Paula L. , Yang, Qi , Childs, Erica J., Hartge, Patricia, Hoover, Robert N. , Li, Donghui , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Walsh, Naomi , Mocci, Evelina , Zhang, Mingfeng , Wang, Zhaoming , Chanock, Stephen Jacob , Kraft, Peter , Risch, Harvey A. , Ámundadóttir, Laufey T. , Yu, Herbert , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 242-242

10.1158/1538-7445.am2018-242 Get It

Abstract Objective Genome-wide association studies (GWAS) identify associations of individual SNPs with cancer risk but usually only explain a fraction of the inherited variability. Pathway analysis of genetic variants has been shown for many disorders to be a powerful tool in discovering novel networks of susceptibility genes. Design We have conducted a large agnostic pathway-based meta-analysis of GWAS data using the summary-based adaptive rank truncated product (sARTP) method to identify novel gene sets and pathways associated with pancreatic ductal adenocarcinoma (PDA) in 9,040 cases and 12,495 controls. We performed expression quantitative trait loci (eQTL) analysis and functional annotation of the top SNPs in genes identified in PDA-associated gene sets and pathways. Results We identified 14 gene sets and pathways associated with PDA at FDR < 0.05. Five of the strongest signals (P-value ≤ 1.3x10-5 Bonferroni corrected) were in genes from KEGG maturity onset diabetes of the young, Reactome regulation of beta cell development, Biocarta role of epidermal growth factor (EGF) receptor transactivation by G-protein-coupled receptors in cardiac hypertrophy pathway, Nikolsky breast cancer chr17q11-q21 amplicon gene set, and Pujana ATM Pearson correlation coefficient (PCC) network gene set. We identified and validated rs876493 and three correlated SNPs (PGAP3) and rs3124737 (CASP7) as eQTLs in two normal derived pancreas tissue datasets. Conclusion Our agnostic gene set and pathway analysis integrated with functional annotation and eQTL analysis provides novel insight into genes and pathways that may be biologically relevant for risk of PDA. Citation Format: Naomi Walsh, Han Zhang, Paula L. Hyland, Qi Yang, Evelina Mocci, Mingfeng Zhang, Erica J. Childs, Zhaoming Wang, Stephen Chanock, Patricia Hartge, Robert Hoover, Peter Kraft, Donghui Li, Eric J. Jacobs, Gloria M. Petersen, Brian M. Wolpin, Harvey A. Risch, Laufey T. Amundadottir, Kai Yu, Alison P. Klein, Rachael Z. Stolzenberg-Solomon. Large pathway and gene set analysis of GWAS data identifies novel associations for pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 242.
Abstract 1077: Genomic alterations in plasma cell-free DNA predict treatment response to abiraterone acetate and prednisone and survival in metastatic castration-resistant prostate cancer
Du, Meijun , Kohli, Manish , Huang, Chiang‐Ching , Kohli, Manish , Wang, Liang

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 1077-1077

10.1158/1538-7445.am2018-1077 Get It

Abstract Background: Abiraterone acetate/prednisone (AA/P) is used for treatment of metastatic castration-resistant prostate cancer (mCRPC), but response is variable and there are no known molecular predictive factors. Methods: We prospectively collected germline and plasma specimens from 72 mCRPC patients progressing on androgen-deprivation therapy (ADT) before initiating AA/P treatment (baseline) and serially after 12 weeks of treatment. After extracting cell-free DNA (cfDNA), we performed copy number analysis using low pass whole-genome sequencing approach. The primary endpoints were to determine association with response and survival. Cox regression and Kaplan-Meier survival analyses were used to associate the CNV with overall survival (OS) and progression-free survival (PFS) with statistical significance at p≤0.05. For determining primary resistance to AA/P, responders and nonresponders were defined as patients showing no progression or progression after 12 weeks treatment. T-test was used to evaluate the CNV with AA/P response at 12 weeks. Results: Whole-genome sequencing generated approximately 8.0 million mappable sequence reads per subject (total plasma samples sequenced, n=144). By comparing cfDNA to germline control DNA, our copy number analysis showed significant genomic abnormalities in 37 of 144 plasma samples. We observed the most frequent amplification of 1q, 8q, Xq and deletion of 2p, 6q,10q, 13q. Among these CNVs, amplification of MYC at 8q24.21, AR at Xq12, deletion of FOXP1 at 3p14, PTEN at 10q23.31, RB1 at 13q14.2, TP53 at 17P13.1, and gene fusions (TMPRSS2:ERG) were consistent with previous reports from tumor tissue-based studies. Survival analysis showed significant association of a fragment deletion at 13q14-32 with both OS and PFS (FDR= 0.0207/0.0141). The most significant fragment showing association with OS was the deletion of fragment at 2p22.1-p14 (FDR=0.00219). Genomic gains of MYC at 8q24.21 and NCOA2 at 8q13.3 were associated with PFS with FDR= 0.0085 and 0.0072, respectively. By comparing baseline CNVs between responder and nonresponders, we identified significant association of the deletion of PTEN at 10q23.31 (p= 0.0003), RB1 at 13q14.2 (p= 0.0008) and amplification of NCOA2 at 8q13.3 (p= 0.0030) with AA/P response/resistance at 12 weeks. Although statistical analysis showed the significant CNV change at AR locus between baseline and 12-week post-AA/P treatment (p=0.0002), the CNV change was not significantly different between responders and nonresponders (p=0.1697). Conclusions: cfDNA CNV may serve as a sensitive biomarker for prediction of treatment response to AA/P. Further detailed CNV and clinical association analyses are needed to fully validate the potential clinical utilities of cfDNA-based liquid biopsy for clinical management. Citation Format: Meijun Du, Manish Kohli, Chiang-Ching Huang, Liang Wang. Genomic alterations in plasma cell-free DNA predict treatment response to abiraterone acetate and prednisone and survival in metastatic castration-resistant prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1077.
Abstract B201: A phase 1 dose-finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)
Vaishampayan, Ulka N. , Ali, Sarah , Matrana, Marc , Alter, Robert , Edenfield, Jeff, Blanchette, Sarah, Gan, Lu , Vaishampayan, Ulka , Atkins, Michael B. , Joseph, Richard W. , Ho, Thai H. , Wang, Yan , McDermott, David F.

Mayo Clinic

Molecular Cancer Therapeutics | August 17, 2018 | Volume: 17 | Issue: 1_Supplement | Pages: B201-B201

10.1158/1535-7163.targ-17-b201 Get It

Abstract Background: X4P-001 is an orally bioavailable, selective, allosteric inhibitor of the chemokine receptor CXCR4, and has been shown to downregulate hypoxia inducible factor-2α (HIF-2α) and myeloid-derived suppressor cell (MDSC) trafficking in the tumor microenvironment. In multiple RCC xenograft models, the addition of X4P-001 to tyrosine kinase inhibitors (TKIs), including axitinib, has demonstrated increased efficacy and delayed onset of TKI resistance. Methods: This is an ongoing phase 1/2 open-label study of X4P-001 in combination with axitinib in patients (pts) with histologically confirmed clear cell RCC (ccRCC) who have received ≥1 prior systemic therapy. The Ph1 portion of the study evaluates safety, tolerability, PK, PD, and antitumor activity of the combination using a 3+3 dose escalation schema (escalating doses of X4P-001+ axitinib at 5 mg BID). The Ph2 portion is a single-arm expansion cohort evaluating this combination treatment in ~ 45 ccRCC pts. The radiologic assessment is performed every 8 weeks with central review. Results: As of 30 June, 2017, enrollment for the Ph1 portion of the study has been completed. Sixteen (16) pts were enrolled and the median age was 64 years (range 50-76). Pts had received a median of 2 prior lines of therapy (range 1-5). The doses tested were 200 mg BID, 400 and 600 mg QD of X4P-001 + axitinib. There were two dose-limiting toxicities (DLTs) observed at the X4P-001 600 mg QD dose level: one pt had multiple grade (G) 2 adverse events (AEs), including anorexia, cognitive disturbance, fatigue, nausea, vomiting, and somnolence; another pt had G3 dyspnea and fatigue. The MTD/RP2D was determined to be 400 mg QD of X4P-001 + axitinib. Treatment-related AEs (≥ 10%) of any grade were diarrhea, fatigue, hypertension, nausea, headache, anorexia, vomiting, dry eye, dysphonia, abnormal loss of weight, increased lipase, proteinuria, dry mouth, stomatitis, cognitive disorder, dysgeusia, and palmar-plantar erythrodysaesthesia syndrome. Treatment-related G3/4 AEs (≥ 10%) were hypertension. In addition, one pt had SAE due to G2 diarrhea and G2 creatinine elevation. Drug exposures (AUC0-24hr) at steady state (SS) are similar for 200 mg BID and 400 mg QD dose. Mean Cmax and AUC0-24hr at SS increased approximately 1.6- and 1.9-fold, respectively, from 400 mg to 600 mg QD dose. Leukocyte mobilization is a well-established surrogate marker for CXCR4 inhibition. At both 400 mg and 600 mg daily dose levels, X4P-001 demonstrated approximately 2 to 2.5-fold increase of WBC (range: 1.4-4.7 fold) and nearly 4-fold increase of CD34+ progenitor cells (range: 1.8-6.4 fold). The peak elevation of both markers occurred around 2 to 4 hours following dosing. Of the 12 clinically evaluable pts, 3 had confirmed partial response, 8 had stable disease, and 1 had progressive disease. As of 30 June 2017, 9 pts remain on study and median duration on treatment was 27 weeks (range 7.4-60). Conclusions: The combination treatment is well tolerated at a dose of 400 mg QD of X4P-001 + axitinib with preliminary evidence of clinical activity. The doses used in this phase I study were biologically active in inhibiting CXCR4 in peripheral blood as demonstrated by elevating WBC and CD34+ cell counts. The Ph2 portion of the study is ongoing. Citation Format: Michael Atkins, Richard Joseph, Thai Ho, Ulka Vaishampayan, Sarah Ali, Marc Matrana, Robert Alter, Jeff Edenfield, Yan Wang, Sarah Blanchette, Lu Gan, David McDermott. A phase 1 dose-finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC) [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B201.
Abstract PR08: Ubiquitin-specific protease 6 (USP6) oncogene confers sensitivity of Ewing sarcoma to interferon cytotoxicity
Henrich, Ian C. , Young, Rob, Quick, Laura , Wang, Xiaoke, Oliveira, André M. , Chou, Margaret M. , Wang, Xiaoke

Mayo Clinic

Clinical Cancer Research | August 17, 2018 | Volume: 24 | Issue: 2_Supplement | Pages: PR08-PR08

10.1158/1557-3265.sarcomas17-pr08 Get It

Abstract Our goal is to identify novel targeted therapies for Ewing sarcoma (ES). ES is a devastating malignancy that predominantly affects children and young adults. It is the second most common cancer of the bone, yet in contrast to many other malignancies, survival rates have not improved for decades. For patients with localized disease, no biomarkers exist to predict recurrence or response to chemotherapy. For those with metastatic disease, chemotherapy is largely ineffective, and 5-year survival rates have stagnated at approximately 20%. Thus, there is an urgent need to identify biomarkers that can predict recurrence and response to therapy, as well as identify novel targeted therapies to combat this lethal disease. USP6 is the key etiologic agent in several benign bone and soft tissue tumors (BSTTs), where its chromosomal translocation results in overexpression. USP6 encodes a deubiquitylating enzyme, and our prior studies identified the tyrosine kinase Jak1 as an essential substrate of USP6 during BSTT development. Jak1 levels are dramatically elevated in USP6-overexpressing cells, leading to phosphorylation and activation of STAT transcription factors. We recently discovered that USP6 is also highly expressed in multiple sarcomas, including ES. Since Jak1-STATs play a central in mediating response to interferon (IFN), we hypothesized that USP6 might cause dysregulated IFN signaling in ES. Microarray and RNA-sequencing analysis revealed that USP6 by itself induced an IFN-response gene signature, both in immortalized, patient-derived ES cells and in primary human ES tumors. USP6+ ES cells were found to be exquisitely sensitive to exogenous IFN compared to USP6- ES cells, with both prolonged and heightened STAT1 and STAT3 activation observed. Furthermore, IFN selectively induced apoptosis of USP6+ but not USP6- ES cells. Gene expression analysis confirmed that in USP6+ ES cells, IFN synergistically induced expression of numerous IFN-stimulated genes (ISGs), including the pro-apoptotic ligand TRAIL. CRISPR-mediated depletion of TRAIL completely abrogated IFN-induced death of USP6+ ES cells. In sum, these results identify USP6 as a potential novel biomarker that may predict sensitivity of ES to targeted IFN therapy. This abstract is also being presented as Poster B11. Citation Format: Ian Henrich, Rob Young, Laura Quick, Xiaoke Wang, Andre Oliveira, Margaret Chou. Ubiquitin-specific protease 6 (USP6) oncogene confers sensitivity of Ewing sarcoma to interferon cytotoxicity [abstract]. In: Proceedings of the AACR Conference on Advances in Sarcomas: From Basic Science to Clinical Translation; May 16-19, 2017; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(2_Suppl):Abstract nr PR08.
Neuropilin‐1 maintains dimethylarginine dimethylaminohydrolase 1 expression in endothelial cells, and contributes to protection from angiotensin II–induced hypertension
Wang, Ying , Wang, Enfeng , Zhang, Yuebo , Madamsetty, Vijay Sagar , Ji, Baoan , Grande, Joseph P. , Misra, Sanjay , Madamsetty, Vijay S, Radisky, Derek C. , Misra, Sanjay , Madamsetty, Vijay S , Mukhopadhyay, Debabrata , Wang, Ying

Mayo Clinic

The FASEB Journal | August 17, 2018 | Volume: 33 | Issue: 1 | Pages: 494-500

10.1096/fj.201800499r | PMID 30118322 Get It

ABSTRACT Dimethylarginine dimethylaminohydrolases (DDAHs) are known to degrade asymmetric dimethylarginine, an endogenous inhibitor of NOS, and maintain vascular homeostasis; however, the regulatory pathways of DDAHs remain unclear. In this study, we aimed to define the role of transmembrane glycoprotein neuropilin‐1 (NRP1) in the expression of DDAHs and investigate the potential roles of NRP1 in regulation of blood pressure. Short hairpin RNA–mediated knockdown of NRP1 reduced the level and mRNA stability of DDAH1 but not DDAH2 in HUVECs, whereas overexpression of NRP1 increased the mRNA stability of DDAH1. Meanwhile, mesenteric arteries and lung vascular endothelial cells of tamoxifen‐inducible endothelial cell–specific NRP1 knockout mice exhibited decreased expression of DDAH1 and slightly increased expression of DDAH2. Mechanistically, the regulation of NRP1 on DDAH1 expression is mediated by a posttranscriptional mechanism involving miR‐219‐5p in HUVECs. Although the endothelial cell–specific NRP1 knockout mice did not exhibit any significant change in blood pressure at the basal level, they were more sensitive to low‐dose angiotensin II infusion–induced increases in blood pressure. Our results show that NRP1 is required for full expression of DDAH1 in endothelial cells and that NRP1 contributes to protection from low‐dose angiotensin II–induced increases in blood pressure.—Wang, Y., Wang, E., Zhang, Y., Madamsetty, V. S., Ji, B., Radisky, D. C., Grande, J. P., Misra, S., Mukhopadhyay, D. Neuropilin‐1 maintains dimethylarginine dimethylaminohydrolase 1 expression in endothelial cells, and contributes to protection from angiotensin II–induced hypertension. FASEB J. 33, 494–500 (2019). www.fasebj.org
Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer
Walsh, Naomi , Hyland, Paula L. , Yang, Qi , Childs, Erica J., Collins, Irene , Wang, Zhaoming , Arslan, Alan A. , Bracci, Paige M. , Brennan, Paul , Canzian, Federico , Gallinger, Steven , Goodman, Gary E. , Goodman, Phyllis J. , Hung, Rayjean J, Kurtz, Robert C. , Scélo, Ghislaine , Shu, Xiao Ou , Visvanathan, Kala , consortia, PanScan and PanC4, Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Borgida, Ayelet , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Chaffee, Kari G. , Foretová, Lenka , Fuchs, Charles S. , Gaziano, J. Michael , Giovannucci, Edward, Hackert, Thilo , Haiman, Christopher A. , Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Herman, Joseph M. , Holly, Elizabeth A., Hoover, Robert N. , Hung, Rayjean J, Janout, Vladimí­r , Klein, Eric A. , Laheru, Daniel A. , Lee, I‐Min , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Strobel, Oliver , Thornquist, Mark, Wactawski‐Wende, Jean , Wareham, Nick, Weiderpass, Elisabete , Wentzensen, Nicolas , Wheeler, William, Zeleniuch‐Jacquotte, Anne , Kraft, Peter , Li, Donghui , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Rabe, Kari G. , Hung, Rayjean J. , Cleary, Sean, Weiderpass, Elisabete , Arslan, Alan A , Canzian, Federico , Hung, Rayjean J , Wactawski-Wende, Jean , Wang, Zhaoming , Visvanathan, Kala , Klein, Eric A , Strobel, Oliver , Kraft, Peter , Porta, Miquel , Real, Francisco X , Zeleniuch-Jacquotte, Anne , Zhang, Han , Mocci, Evelina , Zhang, Mingfeng , Freeman, Laura E. Beane , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Hung, Rayjean J, Kooperberg, Charles , Malats, Núria , Marchand, Loı̈c Le , Neale, Rachel Ε. , Olson, Sara H. , Van Den Eeden, Stephen K , White, Emily , Zheng, Wei , consortia, PanScan and PanC4, Albanes, Demetrius , Bamlet, William R. , Boutron‐Ruault, Marie‐Christine , Brais, Lauren K , Chanock, Stephen Jacob , Cleary, Sean P. , Cotterchio, Michelle , Holcátová, Ivana , Hung, Rayjean J, Lu, Lingeng , Männistö, Satu , Milne, Roger L. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Wareham, Nick, Yu, Kai , Risch, Harvey A. , Ámundadóttir, Laufey T. , Yu, Kai , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 15, 2018 | Volume: 111 | Issue: 6 | Pages: 557-567

10.1093/jnci/djy155 | PMID 30541042 Get It

Sex-specific gene and pathway modeling of inherited glioma risk
Ostrom, Quinn T. , COLEMAN, WARREN, Lathia, Justin D. , Liao, Peter, Wrensch, Margaret , Eckel‐Passow, Jeanette E. , Armstrong, Georgina , Rice, Terri, McCoy, Lucie , Hansen, Helen M. , Bernstein, Jonine L. , Claus, Elizabeth B. , Houlston, Richard S. , Jenkins, Robert B. , Johansen, Christoffer , Lai, Rose , Merrell, Ryan , Sadetzki, Siegal , Schildkraut, Joellen M. , Shete, Sanjay , Andersson, Ulrika , Rajaraman, Preetha , Linet, Martha S. , Wang, Zhaoming , Bracci, Paige M. , Molinaro, Annette M. , Pezmecki, M, Prados, Michael D. , Smirnov, Ivan, Wiemels, Joseph L. , Zheng, Shichun, Visvanathan, Kala , Stevens, Victoria L. , Henriksson, Roger , Feychting, Maria , Ahlbom, Anders , Milne, Graham G Giles Roger, McKean‐Cowdin, Roberta , Stampfer, Meir J. , Ruder, Avima M., Hallmans, Göran , Gaziano, J. Michael , Sesso, Howard D. , Purdue, Mark P. , Peters, Ulrike , Buring, Julie E. , Melin, Beatrice , Bondy, Melissa L. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S , Barnholtz-Sloan, Jill S , Wang, Zhaoming , Visvanathan, Kala , Coleman, Warren, Huang, William Y. C. , Rubin, Joshua B , Berens, Michael E. , Speyer, Gil , Armstrong, Georgina , Wiencke, John K. , Amos, Christopher I. , Il’yasova, Dora , Lachance, Daniel Honore , Olson, Sara H. , Chanock, Stephen Jacob , Yeager, Meredith , Berger, Mitchel S. , Chang, Stephen , Clarke, Jennifer , Molinaro, Annette M. , Perry, Arie , Tihan, Tarık , Walsh, Kyle M. , Freeman, Laura E. Beane , Koutros, Stella , Albanes, Demetrius , Michaud, Dominique S. , Marchand, Loı̈c Le , Carreón, Tania , Zeleniuch‐Jacquotte, Anne , White, Emily , Ostrom, Quinn T

Mayo Clinic

Neuro-Oncology | August 8, 2018 | Volume: 21 | Issue: 1 | Pages: 71-82

10.1093/neuonc/noy135 | PMID 30124908 Get It

Establishing a Current Good Manufacturing Practice Facility for Biomaterials and Biomolecules in an Academic Medical Center
Greenberg, Alexandra J. , Runge, Bethany Kinseth, Solyntjes, Sarah A., Helene-Kraft, Juliana St., Glass, Suzanne L., Waletzki, Brian E., Herrick, James L., Yaszemski, Michael J. , Windebank, Anthony J. , Wang, Huan , Greenberg-Worisek, Alexandra J, St Helene-Kraft, Juliana, Miller, Alan Lee, Miller, Alan Lee , Wang, Huan

Mayo Clinic

Tissue Engineering Part B: Reviews | August 7, 2018 | Volume: 24 | Issue: 6 | Pages: 493-498

10.1089/ten.teb.2018.0114 | PMID 30084747 Get It

Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau
Kang, Silvia S. , Ebbert, Mark , Baker, Kelsey E., Cook, Casey , Wang, Xuewei , Sens, Jonathon , Kocher, Jeanne-Pierre, Petrucelli, Leonard , Fryer, John Denis , Ebbert, Mark T W , Sens, Jonathon P, Fryer, John D

Mayo Clinic

Journal of Experimental Medicine | August 6, 2018 | Volume: 215 | Issue: 9 | Pages: 2235-2245

10.1084/jem.20180653 | PMID 30082275 Get It

Alzheimer’s disease (AD) is an age-associated neurodegenerative disease characterized by amyloidosis, tauopathy, and activation of microglia, the brain resident innate immune cells. We show that a RiboTag translational profiling approach can bypass biases due to cellular enrichment/cell sorting. Using this approach in models of amyloidosis, tauopathy, and aging, we revealed a common set of alterations and identified a central APOE-driven network that converged on CCL3 and CCL4 across all conditions. Notably, aged females demonstrated a significant exacerbation of many of these shared transcripts in this APOE network, revealing a potential mechanism for increased AD susceptibility in females. This study has broad implications for microglial transcriptomic approaches and provides new insights into microglial pathways associated with different pathological aspects of aging and AD.